COVAX
End to end story
Why we need COVAX

With a fast-moving pandemic, no one is safe, unless everyone is safe

- US$375 billion lost to the global economy each month
- Under a business as usual approach, it could take years to develop effective vaccines and decades to ensure they reach everyone that needs them
- Today, historic scientific collaboration, with currently over 200 vaccine candidates in varying stages of development
- Unprecedented commitment from the private sector to work together in the interests of the global public good

Bilateral deals leave many countries behind

High risk of failure in vaccine development

Over 500,000 deaths and counting

Speed, Scale, Access
Our goals

• To develop the largest and most diverse actively managed portfolio of vaccine candidates so that the best vaccines are made available and the world has access to the best science

• To deliver 2 billion doses by end of 2021

• To guarantee fair and equitable access to COVID-19 vaccines for every country in the world
COVAX: an end-to-end solution

Bold ideas and brilliant innovation for the worst global health crisis in 100 years

- World’s largest and most diverse portfolio of Vx candidates
- Speed premium global procurement to share risks
- Equitable access based on fair allocation
How can COVAX secure vaccine supply

**The COVAX risk-sharing approach:**

**Buying into a portfolio of multiple vaccine candidates** allows countries to insure themselves against failure of individual vaccines and secure cost-effective access to successful vaccines.

**Sharing risk of development,** guaranteeing volumes and building manufacturing capacity now means accessing vaccines quickly once proven successful.

**Active portfolio management** ensures maximum return on investment and efficient use of assets as insights in individual assets and portfolio evolves.

**What is needed**

- **July 2020 - December 2020**
  - $11.3 B
  - Commitment of high-income and upper middle-income countries to purchase up to 950 M doses through COVAX Facility
  - Doses for low-income countries and lower middle-income countries to be procured through the Facility via the Gavi COVAX Advance Market Commitment

- **January 2021 - December 2021**
  - $6.8 B
Current CEPI COVID-19 vaccine portfolio consists of 9 projects:

<table>
<thead>
<tr>
<th>Candidate</th>
<th>Location</th>
<th>Platform</th>
<th>Current Phase</th>
</tr>
</thead>
<tbody>
<tr>
<td>AZ / Oxford</td>
<td>UK</td>
<td>Viral Vector</td>
<td>Phase III</td>
</tr>
<tr>
<td>Clover</td>
<td>China</td>
<td>Protein</td>
<td>Phase I</td>
</tr>
<tr>
<td>CureVac</td>
<td>Germany</td>
<td>RNA</td>
<td>Phase I</td>
</tr>
<tr>
<td>Inovio</td>
<td>USA</td>
<td>DNA</td>
<td>Phase I</td>
</tr>
<tr>
<td>Novavax</td>
<td>USA</td>
<td>Protein</td>
<td>Phase I</td>
</tr>
<tr>
<td>Moderna</td>
<td>USA</td>
<td>RNA</td>
<td>Phase IIa</td>
</tr>
<tr>
<td>Merck/Themis</td>
<td>USA/Austria</td>
<td>Viral Vector</td>
<td>Preclinical</td>
</tr>
<tr>
<td>University of Hong Kong</td>
<td>China</td>
<td>Viral Vector</td>
<td>Preclinical</td>
</tr>
<tr>
<td>University of Queensland</td>
<td>Australia</td>
<td>Protein</td>
<td>Preclinical</td>
</tr>
</tbody>
</table>

Speed, Scale, Access
Why we need to build manufacturing capacity now

To deliver 2 billion doses by the end of 2021, 2-3 successful programmes are needed to:

1. Produce early doses to support clinical studies
2. Scale up processes to industrial scale before clinical trials begin
3. Scale-out products in different countries to expand capacity
4. Stockpile vaccines in bulk in anticipation of dose level definition
5. Anticipate projects failing during clinical development
6. Repurpose facilities for successful products, if needed

Speed, Scale, Access
The Allocation Framework and Allocation Mechanism has been built including your feedback

Goal
- Protect public health and minimize societal and economic impact by reducing COVID-19 mortality
- Equal allocation between LICs, LMICs, UMICs and HICs as we seek to reach 20% of the population

Priorities
1. Health and social care workers
   All countries receive doses to cover 3% of their population

2. High-risk adults
   All countries receive additional doses to cover a total of 20% of their population (in tranches)

3. Further priority groups
   Countries receive doses to cover more than 20% of their population

Timing
- Countries receive doses proportionally to their total population

- Timing is based on country need, vulnerability and COVID-19 threat

A buffer will also be set aside for emergency deployment based on immediate needs
COVAX Facility

Gavi COVAX AMC
(ODA-based)

Vaccine supply guarantees

Self-financing country contributions

Available doses of successful vaccine(s)
from COVAX Facility Portfolio

Dedicated doses
LICs, LMICs, and IDA eligible small economies

Dedicated doses
HICs and UMICs
Why COVAX Matters

- Doses for at least 20% of your population
- End the acute phase of the pandemic
- Diverse and actively managed portfolio of vaccines
- Rebuild economies
- Vaccines delivered as soon as they are available
How you can participate

**Self-financing countries:**

- Letters sent to Missions 3 July
- Deadline to Submit Letter of Interest by 10 July
- Self-pay country consultation 16&17 July
- Final commitments 31 Aug

**AMC-supported countries:**

- Letters sent to Missions 6 July
- Invitation to submit indication of interest ongoing
- AMC-supported country consultation 20&21 July
- Submission of application to join COVAX AMC Fall (tbc)
One World, Protected: This is how far we’ve come

<table>
<thead>
<tr>
<th>Access to the world’s largest and most diversified portfolio</th>
<th>9 candidates currently, expanding further: AZ/Oxford University, Clover Biopharma, CureVac, Inovio, Novavax, Moderna, Merck/Themis, University of Hong Kong, University of Queensland</th>
<th>4+ technologies: mRNA, DNA, protein, viral vector</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fastest way to get to a safe and efficacious vaccine</td>
<td>Manufacturing today already under way, incl. capacity build-up, preparation for tech transfers, etc.</td>
<td>Q4 2020 Potentially some candidates that could achieve emergency use approval</td>
</tr>
<tr>
<td>Volumes and funding secured</td>
<td>300+ million doses secured to date; more volume underway</td>
<td>$2 billion in funding secured</td>
</tr>
<tr>
<td>Equitable global access and risk pooling</td>
<td>Champion equity through WHO’s fair allocation framework and emergency buffer</td>
<td>Shared risk through pooled procurement of “COVAX Facility”</td>
</tr>
</tbody>
</table>
Key elements

COVAX pillar is an end-to-end solution
Key elements

COVAX pillar is an end-to-end solution

All elements need to be funded in parallel for COVAX to be successful
Key elements

1. COVAX pillar is an end-to-end solution
2. All elements need to be funded in parallel for COVAX to be successful
3. The more countries participate, the higher the chances of success are